Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial

References

• Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10:778 - 90; http://dx.doi.org/10.1016/S1473-3099(10)70194-8; PMID: 20961813
   PubMed Web of Science ®Google Scholar
• Lee MS, Chiang PS, Luo ST, Huang ML, Liou GY, Tsao KC, Lin TY. Incidence rates of enterovirus 71 infections in young children during a nationwide epidemic in Taiwan, 2008-09. PLoS Negl Trop Dis 2012; 6:e1476; http://dx.doi.org/10.1371/journal.pntd.0001476; PMID: 22348156
   PubMed Web of Science ®Google Scholar
• Liang Z, Mao Q, Gao Q, Li X, Dong C, Yu X, Yao X, Li F, Yin W, Li Q, et al. Establishing China’s national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 2011; 29:9668 - 74; http://dx.doi.org/10.1016/j.vaccine.2011.10.018; PMID: 22015395
   PubMed Web of Science ®Google Scholar
• Ministry of Health of the People’s Republic of China. National notifiable diseases report. Available from: http://www.chinacdc.cn/tjsj/fdcrbbg
   Google Scholar
• Chua KB, Kasri AR. Hand foot and mouth disease due to enterovirus 71 in Malaysia. Virol Sin 2011; 26:221 - 8; http://dx.doi.org/10.1007/s12250-011-3195-8; PMID: 21847753
   PubMedGoogle Scholar
• Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR, Taiwan Enterovirus Epidemic Working Group. An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med 1999; 341:929 - 35; http://dx.doi.org/10.1056/NEJM199909233411301; PMID: 10498487
   PubMed Web of Science ®Google Scholar
• Wang Y, Feng Z, Yang Y, Self S, Gao Y, Longini IM, Wakefield J, Zhang J, Wang L, Chen X, et al. Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology 2011; 22:781 - 92; http://dx.doi.org/10.1097/EDE.0b013e318231d67a; PMID: 21968769
   PubMed Web of Science ®Google Scholar
• Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, Gao F, Wu X, Xu M, Wang JZ. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother 2013; 9:1701 - 5; http://dx.doi.org/10.4161/hv.24949; PMID: 23744508
   PubMed Web of Science ®Google Scholar
• Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013; 381:2024 - 32; http://dx.doi.org/10.1016/S0140-6736(13)61049-1; PMID: 23726161
   PubMed Web of Science ®Google Scholar
• WHO. Clinical considerations for evaluation of vaccines for prequalification. Points to consider for manufacturers of human vaccines. 2010 [cited 2013 September 12]. Available from:http://www.who.int/immunization_standards/vaccine_quality/clinical_considerations_oct10.pdf
   Google Scholar
• Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996; 272:54 - 60; http://dx.doi.org/10.1126/science.272.5258.54; PMID: 8600537
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Note for guidance on the clinical evaluation of vaccines. 2005 [cited 2013 September 12] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003875.pdf
   Google Scholar
• Hendriksen C, Arciniega JL, Bruckner L, Chevalier M, Coppens E, Descamps J, Duchêne M, Dusek DM, Halder M, Kreeftenberg H, et al. The consistency approach for the quality control of vaccines. Biologicals 2008; 36:73 - 7; http://dx.doi.org/10.1016/j.biologicals.2007.05.002; PMID: 17892948
   PubMed Web of Science ®Google Scholar
• Statistics JN. in Clinical Vaccine Trials. Springer, 2010.
   Google Scholar
• Talbot HK, Keitel W, Cate TR, Treanor J, Campbell J, Brady RC, Graham I, Dekker CL, Ho D, Winokur P, et al. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine 2008; 26:4057 - 61; http://dx.doi.org/10.1016/j.vaccine.2008.05.024; PMID: 18602726
   PubMed Web of Science ®Google Scholar
• Jones RL, Froeschle JE, Atmar RL, Matthews JS, Sanders R, Pardalos J, Moeller L, Chin JE, Famula M, Briggs DJ, et al. Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine. Vaccine 2001; 19:4635 - 43; http://dx.doi.org/10.1016/S0264-410X(01)00238-9; PMID: 11535311
   PubMed Web of Science ®Google Scholar
• Jiang WP, Chen JT, Wang X, Wang YL, Liu Y, Chen WY, Xu WG, Qiu YZ, Yin WD. Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive): a double-blind, randomized and controlled trial. Vaccine 2008; 26:2297 - 301; http://dx.doi.org/10.1016/j.vaccine.2007.11.008; PMID: 18395305
   PubMed Web of Science ®Google Scholar
• Ganju J, Izu A, Anemona A. Sample size for equivalence trials: a case study from a vaccine lot consistency trial. Stat Med 2008; 27:3743 - 54; http://dx.doi.org/10.1002/sim.3273; PMID: 18416439
   PubMed Web of Science ®Google Scholar
• Hu YM, Wang X, Wang JZ, Wang L, Zhang YJ, Chang L, Liang ZL, Xia JL, Dai QG, Hu YL, et al. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months. Clin Vaccine Immunol 2013; 20:1805 - 11; http://dx.doi.org/10.1128/CVI.00491-13; PMID: 24108780
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Dobson S, Bernstein DI, Fowler S, Romanowski B, Leroux-Roels I, et al. Clinical evaluation to confirm the manufacturing consistency of three lots of an adjuvanted glycoprotein D genital herpes vaccine in healthy seronegative pre-teen and adolescent girls: A phase III multi-center double-blind randomized trial. Trials in Vaccinology 2013; 2:10 - 8; http://dx.doi.org/10.1016/j.trivac.2013.03.001
   Google Scholar
• Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, Chang SC, Chou AH, Chang JY, Jiang RH, Hsieh YC, et al. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 2013; 31:2471 - 6; http://dx.doi.org/10.1016/j.vaccine.2013.03.015; PMID: 23541623
   PubMed Web of Science ®Google Scholar
• Li YP, Liang ZL, Xia JL, Wu JY, Wang L, Song LF, Mao QY, Wen SQ, Huang RG, Hu YS, et al. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial. J Infect Dis 2014; 209:46 - 55; http://dx.doi.org/10.1093/infdis/jit429; PMID: 23922377
   PubMed Web of Science ®Google Scholar
• Zhu FC, Liang ZL, Li XL, Ge HM, Meng FY, Mao QY, Zhang YT, Hu YM, Zhang ZY, Li JX, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013; 381:1037 - 45; http://dx.doi.org/10.1016/S0140-6736(12)61764-4; PMID: 23352749
   PubMed Web of Science ®Google Scholar
• ERADICATION P. Manual for the virological investigation of poliomyelitis. 1997 [cited 2013 September 12] Available from: http://whqlibdoc.who.int/Hq/1990/WHO_EPI_CDS_POLIO_90.1.pdf
   Google Scholar
• State Food and Drug Administration. The standard guidelines for adverse reactions grading of vaccine clinical trials. 2005 [cited 2013 September 12] Available from: http://www.sda.gov.cn/WS01/CL0844/9350_5html
   Google Scholar